Immune Thrombocytopenia and Treatment-associated Changes in Platelet-associated Antibodies and Cytokine/T-cell Profiles
DOI:
https://doi.org/10.18502/ijaai.v25i6.22649Keywords:
Autoantibodies; Chinese herbal; C-reactive protein; Cyclosporine; Drugs, Idiopathic; Interleukin-6; Prednisone; Purpura, Thrombocytopenic, T-lymphocyte subsetsAbstract
To evaluate whether adjunctive Modified GuiPi Decoction provides additional benefit to standard immunosuppressive therapy in adult patients with chronic immune thrombocytopenia (ITP).
This retrospective cohort study included 120 adult patients aged 18–65 years, diagnosed with ITP according to the 2016 Chinese Expert Consensus. Patients received either standard therapy (cyclosporine A plus prednisone; comparison group, n= 60) or standard therapy plus Modified GuiPi Decoction (treatment group, n= 60) between July 2022 and July 2024.
After 12 weeks of treatment, the treatment group showed significantly greater improvement in fatigue severity score (mean reduction: 3.2 vs 1.8) and quality-of-life index (mean increase: 15.4 vs 9.1) compared to the comparison group. However, no significant between-group difference was observed in platelet count recovery (mean increase: 45.3 × 109/L vs 53.1 × 109/L), with the comparison group showing a numerically larger rise. Mild ALT/AST elevations were more pronounced in the treatment group.
In adult ITP patients, adjunctive Modified GuiPi Decoction may offer symptomatic and quality-of-life benefits beyond standard therapy, but did not demonstrate superior hematological response. Caution is warranted regarding potential hepatotoxicity.
